The estimated Net Worth of M Kathleen Behrens is at least $25.2 Milhão dollars as of 3 July 2024. M Behrens owns over 15,000 units of Sarepta Therapeutics Inc stock worth over $24,630,209 and over the last 12 years he sold SRPT stock worth over $0. In addition, he makes $606,355 as Independent Chairwoman of the Board at Sarepta Therapeutics Inc.
M has made over 18 trades of the Sarepta Therapeutics Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he exercised 15,000 units of SRPT stock worth $208,500 on 3 July 2024.
The largest trade he's ever made was buying 112,500 units of Sarepta Therapeutics Inc stock on 26 June 2023 worth over $900,000. On average, M trades about 10,148 units every 69 days since 2012. As of 3 July 2024 he still owns at least 191,839 units of Sarepta Therapeutics Inc stock.
You can see the complete history of M Behrens stock trades at the bottom of the page.
Dr. M. Kathleen Behrens Ph.D. serves as Independent Chairwoman of the Board of the Company. She also serves as member of our research and development committee and as a member of and chair of our audit committee. Dr. Behrens served as a member of the President’s Council of Advisors on Science and Technology (PCAST) from 2001 to early 2009 and as Chairwoman of PCAST’s Subcommittee on Personalized Medicine. She has served as a public-market biotechnology securities analyst as well as a venture capitalist focusing on healthcare, technology and related investments. Dr. Behrens was instrumental in the founding of several biotechnology companies, including Protein Design Labs, Inc. and COR Therapeutics, Inc. She worked for Robertson Stephens & Co. from 1983 through 1996, serving as a General Partner and Managing Director. Dr. Behrens continued in her capacity as a General Partner for selected venture funds for RS Investments, an investment management and research firm, from 1996 through December 2009, after management led a buyout of that firm from Bank of America. While Dr. Behrens worked at RS Investments, from 1996 to 2002, she served as a Managing Director at the firm and, from 2003 to December 2009, she served as a consultant to the firm. From 1997 to 2005, she was a director of the Board on Science, Technology and Economic Policy for the National Research Council, and from 1993 to 2000 she was a Director, President and Chairwoman of the National Venture Capital Association. Since December 2009, Dr. Behrens has worked as an independent life sciences consultant and investor. In January 2019, Dr. Behrens was appointed to the board of directors of IGM Biosciences, a publicly-traded biotechnology company that is developing IgM antibodies, initially for oncology indications. In May 2019, Dr. Behrens was appointed to the board of directors of MiMedx Group Inc.,
As the Independent Chairwoman of the Board of Sarepta Therapeutics Inc, the total compensation of M Behrens at Sarepta Therapeutics Inc is $606,355. There are 10 executives at Sarepta Therapeutics Inc getting paid more, with Gilmore O'Neill having the highest compensation of $5,168,110.
M Behrens is 67, he's been the Independent Chairwoman of the Board of Sarepta Therapeutics Inc since 2015. There are 1 older and 13 younger executives at Sarepta Therapeutics Inc. The oldest executive at Sarepta Therapeutics Inc is Hans Wigzell, 82, who is the Independent Director.
M's mailing address filed with the SEC is 215 FIRST STREET, SUITE 415, CAMBRIDGE, MA, 02142.
Over the last 12 years, insiders at Sarepta Therapeutics Inc have traded over $58,674,663 worth of Sarepta Therapeutics Inc stock and bought 827,614 units worth $49,516,406 . The most active insiders traders include John C Martin, Richard Barry, eM Kathleen Behrens. On average, Sarepta Therapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of $2,737,275. The most recent stock trade was executed by Ian Michael Estepan on 30 August 2024, trading 5,985 units of SRPT stock currently worth $822,100.
sarepta therapeutics is a biopharmaceutical company focused on the discovery and development of unique rna-targeted therapeutics for the treatment of rare, infectious and other diseases. the company is primarily focused on rapidly advancing the development of its potentially disease-modifying dmd drug candidates, including its lead dmd product candidate, eteplirsen, designed to skip exon 51. sarepta is also developing therapeutics for the treatment of infectious diseases, such as drug-resistant bacteria and other rare human diseases. for more information, please visit us at www.sarepta.com.
Sarepta Therapeutics Inc executives and other stock owners filed with the SEC include: